$PSTV: Plus Therapeutics Reports Second Quarter 2020 Financial and Business Results AUSTIN, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE)
-- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"
, today announced financial and business results for its Second Quarter Fiscal Year 2020 ended June 30, 2020. Q2 2020 net loss was $1.8 million, or $0.45 per share, including payments to NanoTx LLC of $0.78 million. Net cash used in operating activities for the six months ended June 30, 2020 was approximately $2.9 million. Plus Therapeutics ended Q2 2020 with approximately $9.3 million of cash and cash equivalents. The Plus Therapeutics portfolio has three clinical-stage injectable drugs being developed on a unique nanotechnology platform designed to provide patient benefits through improved formulation and delivery innovation. The Company believes the platform can enable significant potential enhancements of safety, efficacy and convenience for oncology patients and their health providers compared to current standards of care. The lead investigational drug in the Company's licensed radiotherapeutic portfolio is Rhenium NanoLiposomes (RNL(TM)), a nanoliposome-encapsulated radionuclide for several cancer targets. Initially being developed for the treatment of recurrent glioblastoma, RNL is being evaluated in the U.S. NIH/NCI-supported, multi-center ReSPECT(TM) Phase 1 dose-finding clinical trial (NCT01906385). RNL is designed to safely, effectively, and conveniently deliver a very high dose of radiation directly into the brain tumor that is up to 25 times greater than that currently being given to recurrent glioblastoma patients using external beam radiation therapy. H2 2020 Business Expansion Outlook The first half of Fiscal Year 2020 marked the successful implementation of the Company's refined development focus, initial pipeline expansion and optimized cost structure. In the second half of Fiscal Year 2020, the Company intends to focus on a number of additional business objectives and potential milestones: -- Report preliminary RNL(TM) data from the ReSPECT Phase I dose finding trial in recurrent glioblastoma -- Finalize RNL Phase 2/pivotal trial plan in recurrent glioblastoma -- Seek RNL Orphan Drug Designation decisions from regulatory agencies -- Complete evaluations of additional external and internal drug development candidates -- Initiate IND-enabling RNL studies for additional indications -- Explore partnership opportunities for RNL, DocePLUS and DoxoPLUS assets "Following the close of our most recent in-licensing transaction, we have made steady progress in expediting the ReSPECT trial," said Dr. Marc Hedrick, President and Chief Executive Officer of Plus Therapeutics. "The second half of 2020 includes the prospect of further significant advancement for our RNL program-- and for the Company. We believe RNL has the potential of improving brain tumor therapy and that of other difficult to treat radiosensitive tumors." Q2 2020 Financial Highlights -- Net cash used in operating activities was $2.9 million for the six months ended June 30, 2020, compared to $4.4 million during the same period in 2019. -- In Q2 2020, 162,500 series U warrants were exercised, raising $0.36M. -- Q2 2020 loss from continuing operations was $1.8 million, or $ 0.45 per share, compared to $2.3 million, or $5.12 per share for Q2 2019. -- Q2 2020 net loss was $1.8 million, or $0.45 per share, compared to $9.1 million, or $20.67 per share, for Q2 2019, reflecting a loss from discontinued operations of $0 for Q2 2020 and $6.9 million in Q2 2019. Investor Call Today at 5 p.m. EDT The Company plans to hold a conference call and live audio webcast today at 5:00 PM Eastern Time to discuss its financial results and provide a general business update. Event: Plus Therapeutics Second Quarter Fiscal Year 2020 Financial Results Conference Call and Webcast Date: Monday, August 10, 2020 Time: 5:00 PM Eastern Time. Live Call: Phone Number: (877) 402-3914; Conference ID: 5925129 Live Webcast: https://event.on24.com/wcc/r/2402905/A6C80D40192BA72 B1FDF935FEAFD7277 Beginning two hours after the conclusion of the conference call, a replay will be available. Replay: http://ir.plustherapeutics.com/events/default.aspx
https://www.globenewswire.com/news-release/20...sults.html
-- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"
, today announced financial and business results for its Second Quarter Fiscal Year 2020 ended June 30, 2020. Q2 2020 net loss was $1.8 million, or $0.45 per share, including payments to NanoTx LLC of $0.78 million. Net cash used in operating activities for the six months ended June 30, 2020 was approximately $2.9 million. Plus Therapeutics ended Q2 2020 with approximately $9.3 million of cash and cash equivalents. The Plus Therapeutics portfolio has three clinical-stage injectable drugs being developed on a unique nanotechnology platform designed to provide patient benefits through improved formulation and delivery innovation. The Company believes the platform can enable significant potential enhancements of safety, efficacy and convenience for oncology patients and their health providers compared to current standards of care. The lead investigational drug in the Company's licensed radiotherapeutic portfolio is Rhenium NanoLiposomes (RNL(TM)), a nanoliposome-encapsulated radionuclide for several cancer targets. Initially being developed for the treatment of recurrent glioblastoma, RNL is being evaluated in the U.S. NIH/NCI-supported, multi-center ReSPECT(TM) Phase 1 dose-finding clinical trial (NCT01906385). RNL is designed to safely, effectively, and conveniently deliver a very high dose of radiation directly into the brain tumor that is up to 25 times greater than that currently being given to recurrent glioblastoma patients using external beam radiation therapy. H2 2020 Business Expansion Outlook The first half of Fiscal Year 2020 marked the successful implementation of the Company's refined development focus, initial pipeline expansion and optimized cost structure. In the second half of Fiscal Year 2020, the Company intends to focus on a number of additional business objectives and potential milestones: -- Report preliminary RNL(TM) data from the ReSPECT Phase I dose finding trial in recurrent glioblastoma -- Finalize RNL Phase 2/pivotal trial plan in recurrent glioblastoma -- Seek RNL Orphan Drug Designation decisions from regulatory agencies -- Complete evaluations of additional external and internal drug development candidates -- Initiate IND-enabling RNL studies for additional indications -- Explore partnership opportunities for RNL, DocePLUS and DoxoPLUS assets "Following the close of our most recent in-licensing transaction, we have made steady progress in expediting the ReSPECT trial," said Dr. Marc Hedrick, President and Chief Executive Officer of Plus Therapeutics. "The second half of 2020 includes the prospect of further significant advancement for our RNL program-- and for the Company. We believe RNL has the potential of improving brain tumor therapy and that of other difficult to treat radiosensitive tumors." Q2 2020 Financial Highlights -- Net cash used in operating activities was $2.9 million for the six months ended June 30, 2020, compared to $4.4 million during the same period in 2019. -- In Q2 2020, 162,500 series U warrants were exercised, raising $0.36M. -- Q2 2020 loss from continuing operations was $1.8 million, or $ 0.45 per share, compared to $2.3 million, or $5.12 per share for Q2 2019. -- Q2 2020 net loss was $1.8 million, or $0.45 per share, compared to $9.1 million, or $20.67 per share, for Q2 2019, reflecting a loss from discontinued operations of $0 for Q2 2020 and $6.9 million in Q2 2019. Investor Call Today at 5 p.m. EDT The Company plans to hold a conference call and live audio webcast today at 5:00 PM Eastern Time to discuss its financial results and provide a general business update. Event: Plus Therapeutics Second Quarter Fiscal Year 2020 Financial Results Conference Call and Webcast Date: Monday, August 10, 2020 Time: 5:00 PM Eastern Time. Live Call: Phone Number: (877) 402-3914; Conference ID: 5925129 Live Webcast: https://event.on24.com/wcc/r/2402905/A6C80D40192BA72 B1FDF935FEAFD7277 Beginning two hours after the conclusion of the conference call, a replay will be available. Replay: http://ir.plustherapeutics.com/events/default.aspx https://www.globenewswire.com/news-release/20...sults.html
Sojourner here following God, obeying God, and cleaving to Him. The journey is onward.
